26.09.2011 • News • Teva Pharmaceutical Industries • Teva • Shlomo Yanai Teva

Teva To Buy Out Kowa's Interest in Japanese Joint Venture for $150 Million

Teva Pharmaceutical Industries, an Israel-based pharma company, Monday announced that it has planned to buy out its partner, Kowa Company's 50% stake in their Japanese joint venture for $150 million, thus owning the venture completely.

Pursuant to this acquisition, Teva now expects the Japanese venture to do business immediately and become a wholly-owned member of the Teva Group. Teva said it looks to generate more than $800 million in revenues annually, through this buyout, compared to $200 million last year.

Additionally it had also acquired Japanese firm, Taiyo Pharmaceutical Industry for $934 million in July.

Shlomo Yanai, President and CEO of Teva said that with this stronger platform, Teva would be in a better position to further drive penetration of high quality generic pharmaceuticals in Japan.

Interview

Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.